Bohn Stafleu van Loghum, Critical Care, 6(15), p. 1009
DOI: 10.1186/cc10527
Full text: Download
Abstract Reversing the immunoparalysis associated with septic shock remains a priority for improving the outcome of patients suffering from sepsis. The efficacy of future therapies may be better studied under an effective system of patient stratification. Gene expression biomarkers offer a mechanism by which patients may be appropriately stratified in such clinical trials.